Skip to main content
Top
Published in: Current Gastroenterology Reports 4/2012

01-08-2012 | Nutrition and Obesity (S McClave, Section Editor)

Fighting Fire with Fire: Is it Time to Use Probiotics to Manage Pathogenic Bacterial Diseases?

Authors: John Heineman, Sara Bubenik, Stephen McClave, Robert Martindale

Published in: Current Gastroenterology Reports | Issue 4/2012

Login to get access

Abstract

Probiotics, when considered in clinical practice, have traditionally been used for prophylaxis; however, there is growing data suggesting treatment benefits in numerous disease states. In this review, we focus on probiotics as treatment for and prevention of several acute and chronic infectious processes including Helicobacter pylori, Clostridium difficile, necrotizing enterocolitis, ventilator-associated pneumonia, vancomycin-resistant enterococci, and nonalcoholic fatty liver disease. It is inaccurate to generalize findings observed in a single probiotic species to all probiotics. This reasoning is due to the variability of colonizing abilities of native intestinal floras, probiotic or otherwise, secondary to different combinations, doses, and duration of treatments. Given these limitations, multiple animal and human studies have shown anti-inflammatory and selective antimicrobial effects of specific probiotics. Some studies suggest a role for probiotics as supplemental treatment, in combination with antibiotics, for the aforementioned disease processes. It is apparent from this review that the efficacy of probiotics is widely variable and multifaceted. More focused clinical and basic science research is necessary to better understand the treatment potential of various probiotics.
Literature
2.
go back to reference Loprinzi CL, Levitt R, Barton DL, et al. Evaluation of shark cartilage in patients with advanced cancer: a north central cancer treatment group trial. Cancer. 2005;104(1):176–82.PubMedCrossRef Loprinzi CL, Levitt R, Barton DL, et al. Evaluation of shark cartilage in patients with advanced cancer: a north central cancer treatment group trial. Cancer. 2005;104(1):176–82.PubMedCrossRef
3.
go back to reference Bassler W. Civ. no. 99–5782 (WGB). US District Court for the District of New Jersey. 2004. Bassler W. Civ. no. 99–5782 (WGB). US District Court for the District of New Jersey. 2004.
4.
5.
go back to reference Chey WD, Wong BC. Practice Parameters Committee of the American College of Gastroenterology. American college of gastroenterology guideline on the management of helicobacter pylori infection. Am J Gastroenterol. 2007;102(8):1808–25.PubMedCrossRef Chey WD, Wong BC. Practice Parameters Committee of the American College of Gastroenterology. American college of gastroenterology guideline on the management of helicobacter pylori infection. Am J Gastroenterol. 2007;102(8):1808–25.PubMedCrossRef
6.
go back to reference Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut. 2010;59(8):1143–53.PubMedCrossRef Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut. 2010;59(8):1143–53.PubMedCrossRef
7.
go back to reference Michetti P, Dorta G, Wiesel PH, et al. Effect of whey-based culture supernatant of lactobacillus acidophilus (johnsonii) La1 on helicobacter pylori infection in humans. Digestion. 1999;60(3):203–9.PubMedCrossRef Michetti P, Dorta G, Wiesel PH, et al. Effect of whey-based culture supernatant of lactobacillus acidophilus (johnsonii) La1 on helicobacter pylori infection in humans. Digestion. 1999;60(3):203–9.PubMedCrossRef
8.
go back to reference Mukai T, Tomoko A, Sato E, et al. Inhibition of binding of heliobacter pylori to the glycolipid receptors by probiotic lactobacillus reuteri. Immunol Med Microbiol. 2001;32:105–10.CrossRef Mukai T, Tomoko A, Sato E, et al. Inhibition of binding of heliobacter pylori to the glycolipid receptors by probiotic lactobacillus reuteri. Immunol Med Microbiol. 2001;32:105–10.CrossRef
9.
go back to reference Lorca GL, Wadstrom T, Valdez GF, Ljungh A. Lactobacillus acidophilus autolysins inhibit helicobacter pylori in vitro. Curr Microbiol. 2001;42(1):39–44.PubMedCrossRef Lorca GL, Wadstrom T, Valdez GF, Ljungh A. Lactobacillus acidophilus autolysins inhibit helicobacter pylori in vitro. Curr Microbiol. 2001;42(1):39–44.PubMedCrossRef
10.
go back to reference Collado MC, Gonzalez A, Gonzalez R, Hernandez M, Ferrus MA, Sanz Y. Antimicrobial peptides are among the antagonistic metabolites produced by bifidobacterium against helicobacter pylori. Int J Antimicrob Agents. 2005;25(5):385–91.PubMedCrossRef Collado MC, Gonzalez A, Gonzalez R, Hernandez M, Ferrus MA, Sanz Y. Antimicrobial peptides are among the antagonistic metabolites produced by bifidobacterium against helicobacter pylori. Int J Antimicrob Agents. 2005;25(5):385–91.PubMedCrossRef
11.
go back to reference Tong JL, Ran ZH, Shen J, Zhang CX, Xiao SD. Meta-analysis: the effect of supplementation with probiotics on eradication rates and adverse events during helicobacter pylori eradication therapy. Aliment Pharmacol Ther. 2007;25(2):155–68.PubMedCrossRef Tong JL, Ran ZH, Shen J, Zhang CX, Xiao SD. Meta-analysis: the effect of supplementation with probiotics on eradication rates and adverse events during helicobacter pylori eradication therapy. Aliment Pharmacol Ther. 2007;25(2):155–68.PubMedCrossRef
12.
go back to reference Szajewska H, Horvath A, Piwowarczyk A. Meta-analysis: the effects of saccharomyces boulardii supplementation on helicobacter pylori eradication rates and side effects during treatment. Aliment Pharmacol Ther. 2010;32(9):1069–79.PubMedCrossRef Szajewska H, Horvath A, Piwowarczyk A. Meta-analysis: the effects of saccharomyces boulardii supplementation on helicobacter pylori eradication rates and side effects during treatment. Aliment Pharmacol Ther. 2010;32(9):1069–79.PubMedCrossRef
13.
go back to reference Cindoruk M, Erkan G, Karakan T, Dursun A, Unal S. Efficacy and safety of saccharomyces boulardii in the 14-day triple anti-helicobacter pylori therapy: a prospective randomized placebo-controlled double-blind study. Helicobacter. 2007;12(4):309–16.PubMedCrossRef Cindoruk M, Erkan G, Karakan T, Dursun A, Unal S. Efficacy and safety of saccharomyces boulardii in the 14-day triple anti-helicobacter pylori therapy: a prospective randomized placebo-controlled double-blind study. Helicobacter. 2007;12(4):309–16.PubMedCrossRef
14.
go back to reference Cremonini F, Di Caro S, Covino M, et al. Effect of different probiotic preparations on anti-helicobacter pylori therapy-related side effects: a parallel group, triple blind, placebo-controlled study. Am J Gastroenterol. 2002;97(11):2744–9.PubMedCrossRef Cremonini F, Di Caro S, Covino M, et al. Effect of different probiotic preparations on anti-helicobacter pylori therapy-related side effects: a parallel group, triple blind, placebo-controlled study. Am J Gastroenterol. 2002;97(11):2744–9.PubMedCrossRef
15.
go back to reference Duman DG, Bor S, Ozutemiz O, et al. Efficacy and safety of saccharomyces boulardii in prevention of antibiotic-associated diarrhoea due to helicobacterpylori eradication. Eur J Gastroenterol Hepatol. 2005;17(12):1357–61.PubMedCrossRef Duman DG, Bor S, Ozutemiz O, et al. Efficacy and safety of saccharomyces boulardii in prevention of antibiotic-associated diarrhoea due to helicobacterpylori eradication. Eur J Gastroenterol Hepatol. 2005;17(12):1357–61.PubMedCrossRef
16.
go back to reference Hurduc V, Plesca D, Dragomir D, Sajin M, Vandenplas Y. A randomized, open trial evaluating the effect of saccharomyces boulardii on the eradication rate of helicobacter pylori infection in children. Acta Paediatr. 2009;98(1):127–31.PubMedCrossRef Hurduc V, Plesca D, Dragomir D, Sajin M, Vandenplas Y. A randomized, open trial evaluating the effect of saccharomyces boulardii on the eradication rate of helicobacter pylori infection in children. Acta Paediatr. 2009;98(1):127–31.PubMedCrossRef
17.
go back to reference Song MJ, Park DI, Park JH, et al. The effect of probiotics and mucoprotective agents on PPI-based triple therapy for eradication of helicobacter pylori. Helicobacter. 2010;15(3):206–13.PubMedCrossRef Song MJ, Park DI, Park JH, et al. The effect of probiotics and mucoprotective agents on PPI-based triple therapy for eradication of helicobacter pylori. Helicobacter. 2010;15(3):206–13.PubMedCrossRef
18.
go back to reference Kelesidis T, Pothoulakis C. Efficacy and safety of the probiotic saccharomyces boulardii for the prevention and therapy of gastrointestinal disorders. Therap Adv Gastroenterol. 2012;5(2):111–25.PubMedCrossRef Kelesidis T, Pothoulakis C. Efficacy and safety of the probiotic saccharomyces boulardii for the prevention and therapy of gastrointestinal disorders. Therap Adv Gastroenterol. 2012;5(2):111–25.PubMedCrossRef
19.
go back to reference Safdar N, Maki DG. The commonality of risk factors for nosocomial colonization and infection with antimicrobial-resistant staphylococcus aureus, enterococcus, gram-negative bacilli, clostridium difficile, and candida. Ann Intern Med. 2002;136(11):834–44.PubMed Safdar N, Maki DG. The commonality of risk factors for nosocomial colonization and infection with antimicrobial-resistant staphylococcus aureus, enterococcus, gram-negative bacilli, clostridium difficile, and candida. Ann Intern Med. 2002;136(11):834–44.PubMed
20.
go back to reference Drekonja DM, Butler M, MacDonald R, et al. Comparative effectiveness of clostridium difficile treatments: a systematic review. Ann Intern Med. 2011;155(12):839–47.PubMed Drekonja DM, Butler M, MacDonald R, et al. Comparative effectiveness of clostridium difficile treatments: a systematic review. Ann Intern Med. 2011;155(12):839–47.PubMed
21.
go back to reference McFarland LV, Surawicz CM, Greenberg RN, et al. A randomized placebo-controlled trial of saccharomyces boulardii in combination with standard antibiotics for clostridium difficile disease. JAMA. 1994;271(24):1913–8.PubMedCrossRef McFarland LV, Surawicz CM, Greenberg RN, et al. A randomized placebo-controlled trial of saccharomyces boulardii in combination with standard antibiotics for clostridium difficile disease. JAMA. 1994;271(24):1913–8.PubMedCrossRef
22.
go back to reference Surawicz C, McFarland L, Greenberg R. The search for a better treatment for recurrent clostridium difficile disease: Use of high-dose vancomycin combine with saccharomyces boulardii. Clin Infect Dis. 2000;31:1012–1017. Surawicz C, McFarland L, Greenberg R. The search for a better treatment for recurrent clostridium difficile disease: Use of high-dose vancomycin combine with saccharomyces boulardii. Clin Infect Dis. 2000;31:1012–1017.
23.
go back to reference Lawrence SJ, Korzenik JR, Mundy LM. Probiotics for recurrent clostridium difficile disease. J Med Microbiol. 2005;54(Pt 9):905–6.PubMedCrossRef Lawrence SJ, Korzenik JR, Mundy LM. Probiotics for recurrent clostridium difficile disease. J Med Microbiol. 2005;54(Pt 9):905–6.PubMedCrossRef
24.
go back to reference McFarland LV. Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of clostridium difficile disease. Am J Gastroenterol. 2006;101(4):812–22.PubMedCrossRef McFarland LV. Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of clostridium difficile disease. Am J Gastroenterol. 2006;101(4):812–22.PubMedCrossRef
25.
go back to reference Hickson M, D'Souza AL, Muthu N, et al. Use of probiotic lactobacillus preparation to prevent diarrhoea associated with antibiotics: randomised double blind placebo controlled trial. BMJ. 2007;335(7610):80.PubMedCrossRef Hickson M, D'Souza AL, Muthu N, et al. Use of probiotic lactobacillus preparation to prevent diarrhoea associated with antibiotics: randomised double blind placebo controlled trial. BMJ. 2007;335(7610):80.PubMedCrossRef
26.
go back to reference Pillai A, Nelson R. Probiotics for treatment of clostridium difficile-associated colitis in adults. Cochrane Database Syst Rev. 2008;(1)(1):CD004611. Pillai A, Nelson R. Probiotics for treatment of clostridium difficile-associated colitis in adults. Cochrane Database Syst Rev. 2008;(1)(1):CD004611.
27.
go back to reference Thilo E, Rosenberg A. The newborn infant. Current Diagnosis & Treatment (20th Edition): Pediatrics. 2011. Thilo E, Rosenberg A. The newborn infant. Current Diagnosis & Treatment (20th Edition): Pediatrics. 2011.
28.
go back to reference Frost BL, Caplan MS. Probiotics and prevention of neonatal necrotizing enterocolitis. Curr Opin Pediatr. 2011;23(2):151–5.PubMedCrossRef Frost BL, Caplan MS. Probiotics and prevention of neonatal necrotizing enterocolitis. Curr Opin Pediatr. 2011;23(2):151–5.PubMedCrossRef
29.
go back to reference Bin-Nun A, Bromiker R, Wilschanski M, et al. Oral probiotics prevent necrotizing enterocolitis in very low birth weight neonates. J Pediatr. 2005;147(2):192–6.PubMedCrossRef Bin-Nun A, Bromiker R, Wilschanski M, et al. Oral probiotics prevent necrotizing enterocolitis in very low birth weight neonates. J Pediatr. 2005;147(2):192–6.PubMedCrossRef
30.
go back to reference Lin HC, Hsu CH, Chen HL, et al. Oral probiotics prevent necrotizing enterocolitis in very low birth weight preterm infants: a multicenter, randomized, controlled trial. Pediatrics. 2008;122(4):693–700.PubMedCrossRef Lin HC, Hsu CH, Chen HL, et al. Oral probiotics prevent necrotizing enterocolitis in very low birth weight preterm infants: a multicenter, randomized, controlled trial. Pediatrics. 2008;122(4):693–700.PubMedCrossRef
31.
go back to reference Deshpande G, Rao S, Patole S, Bulsara M. Updated meta-analysis of probiotics for preventing necrotizing enterocolitis in preterm neonates. Pediatrics. 2010;125(5):921–30.PubMedCrossRef Deshpande G, Rao S, Patole S, Bulsara M. Updated meta-analysis of probiotics for preventing necrotizing enterocolitis in preterm neonates. Pediatrics. 2010;125(5):921–30.PubMedCrossRef
32.
go back to reference Alfaleh K, Anabrees J, Bassler D, Al-Kharfi T. Probiotics for prevention of necrotizing enterocolitis in preterm infants. Cochrane Database Syst Rev. 2011;(3)(3):CD005496. Alfaleh K, Anabrees J, Bassler D, Al-Kharfi T. Probiotics for prevention of necrotizing enterocolitis in preterm infants. Cochrane Database Syst Rev. 2011;(3)(3):CD005496.
33.
go back to reference Morrow LE, Kollef MH, Casale TB. Probiotic prophylaxis of ventilator-associated pneumonia: a blinded, randomized, controlled trial. Am J Respir Crit Care Med. 2010;182(8):1058–64.PubMedCrossRef Morrow LE, Kollef MH, Casale TB. Probiotic prophylaxis of ventilator-associated pneumonia: a blinded, randomized, controlled trial. Am J Respir Crit Care Med. 2010;182(8):1058–64.PubMedCrossRef
34.
go back to reference Sachdev G, Napolitano LM. Postoperative pulmonary complications: Pneumonia and acute respiratory failure. Surg Clin North Am. 2012;92(2):321–44, ix. Sachdev G, Napolitano LM. Postoperative pulmonary complications: Pneumonia and acute respiratory failure. Surg Clin North Am. 2012;92(2):321–44, ix.
35.
go back to reference Napolitano LM. Perspectives in surgical infections: what does the future hold? Surg Infect (Larchmt). 2010;11(2):111–23.CrossRef Napolitano LM. Perspectives in surgical infections: what does the future hold? Surg Infect (Larchmt). 2010;11(2):111–23.CrossRef
36.
go back to reference Klarin B, Molin G, Jeppsson B, Larsson A. Use of the probiotic lactobacillus plantarum 299 to reduce pathogenic bacteria in the oropharynx of intubated patients: a randomised controlled open pilot study. Crit Care. 2008;12(6):R136.PubMedCrossRef Klarin B, Molin G, Jeppsson B, Larsson A. Use of the probiotic lactobacillus plantarum 299 to reduce pathogenic bacteria in the oropharynx of intubated patients: a randomised controlled open pilot study. Crit Care. 2008;12(6):R136.PubMedCrossRef
37.
go back to reference Siempos II, Ntaidou TK, Falagas ME. Impact of the administration of probiotics on the incidence of ventilator-associated pneumonia: a meta-analysis of randomized controlled trials. Crit Care Med. 2010;38(3):954–62.PubMedCrossRef Siempos II, Ntaidou TK, Falagas ME. Impact of the administration of probiotics on the incidence of ventilator-associated pneumonia: a meta-analysis of randomized controlled trials. Crit Care Med. 2010;38(3):954–62.PubMedCrossRef
38.
go back to reference Schultz MJ, Haas LE. Antibiotics or probiotics as preventive measures against ventilator-associated pneumonia: a literature review. Crit Care. 2011;15(1):R18.PubMedCrossRef Schultz MJ, Haas LE. Antibiotics or probiotics as preventive measures against ventilator-associated pneumonia: a literature review. Crit Care. 2011;15(1):R18.PubMedCrossRef
39.
go back to reference Vidal M, Forestier C, Charbonnel N, Henard S, Rabaud C, Lesens O. Probiotics and intestinal colonization by vancomycin-resistant enterococci in mice and humans. J Clin Microbiol. 2010;48(7):2595–8.PubMedCrossRef Vidal M, Forestier C, Charbonnel N, Henard S, Rabaud C, Lesens O. Probiotics and intestinal colonization by vancomycin-resistant enterococci in mice and humans. J Clin Microbiol. 2010;48(7):2595–8.PubMedCrossRef
40.
go back to reference Kim AS. Using the good to beat out the bad: probiotics for eliminating vancomycin-resistant enterococci colonization. J Clin Gastroenterol. 2011;45(10):844–5.PubMedCrossRef Kim AS. Using the good to beat out the bad: probiotics for eliminating vancomycin-resistant enterococci colonization. J Clin Gastroenterol. 2011;45(10):844–5.PubMedCrossRef
41.
go back to reference Mlynarczyk A, Szymanek-Majchrzak K, Kosykowska E, et al. The dominant sequence types of vancomycin-resistant enterococcus faecium among transplantation ward patients. Transplant Proc. 2011;43(8):3132–4.PubMedCrossRef Mlynarczyk A, Szymanek-Majchrzak K, Kosykowska E, et al. The dominant sequence types of vancomycin-resistant enterococcus faecium among transplantation ward patients. Transplant Proc. 2011;43(8):3132–4.PubMedCrossRef
42.
go back to reference Manley KJ, Fraenkel MB, Mayall BC, Power DA. Probiotic treatment of vancomycin-resistant enterococci: a randomised controlled trial. Med J Aust. 2007;186(9):454–7.PubMed Manley KJ, Fraenkel MB, Mayall BC, Power DA. Probiotic treatment of vancomycin-resistant enterococci: a randomised controlled trial. Med J Aust. 2007;186(9):454–7.PubMed
43.
go back to reference Szachta P, Ignys I, Cichy W. An evaluation of the ability of the probiotic strain lactobacillus rhamnosus GG to eliminate the gastrointestinal carrier state of vancomycin-resistant enterococci in colonized children. J Clin Gastroenterol. 2011;45(10):872–7.PubMedCrossRef Szachta P, Ignys I, Cichy W. An evaluation of the ability of the probiotic strain lactobacillus rhamnosus GG to eliminate the gastrointestinal carrier state of vancomycin-resistant enterococci in colonized children. J Clin Gastroenterol. 2011;45(10):872–7.PubMedCrossRef
44.
go back to reference Ioannou GN, Boyko EJ, Lee SP. The prevalence and predictors of elevated serum aminotransferase activity in the united states in 1999–2002. Am J Gastroenterol. 2006;101(1):76–82.PubMedCrossRef Ioannou GN, Boyko EJ, Lee SP. The prevalence and predictors of elevated serum aminotransferase activity in the united states in 1999–2002. Am J Gastroenterol. 2006;101(1):76–82.PubMedCrossRef
45.
go back to reference Clark JM, Brancati FL, Diehl AM. Nonalcoholic fatty liver disease. Gastroenterology. 2002;122(6):1649–57.PubMedCrossRef Clark JM, Brancati FL, Diehl AM. Nonalcoholic fatty liver disease. Gastroenterology. 2002;122(6):1649–57.PubMedCrossRef
46.
go back to reference Li Z, Yang S, Lin H, et al. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology. 2003;37(2):343–50.PubMedCrossRef Li Z, Yang S, Lin H, et al. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology. 2003;37(2):343–50.PubMedCrossRef
47.
go back to reference Cani PD, Delzenne NM. The role of the gut microbiota in energy metabolism and metabolic disease. Curr Pharm Des. 2009;15(13):1546–58.PubMedCrossRef Cani PD, Delzenne NM. The role of the gut microbiota in energy metabolism and metabolic disease. Curr Pharm Des. 2009;15(13):1546–58.PubMedCrossRef
48.
go back to reference Loguercio C, Federico A, Tuccillo C, et al. Beneficial effects of a probiotic VSL#3 on parameters of liver dysfunction in chronic liver diseases. J Clin Gastroenterol. 2005;39(6):540–3.PubMedCrossRef Loguercio C, Federico A, Tuccillo C, et al. Beneficial effects of a probiotic VSL#3 on parameters of liver dysfunction in chronic liver diseases. J Clin Gastroenterol. 2005;39(6):540–3.PubMedCrossRef
49.
go back to reference Lirussi F, Mastropasqua E, Orando S. No evidence to support or refute probiotics for patients with non-alcoholic fatty liver disease and/or steatohepatitis. Cochrane Database of Systematic Reviews. 2007;CD005165. Lirussi F, Mastropasqua E, Orando S. No evidence to support or refute probiotics for patients with non-alcoholic fatty liver disease and/or steatohepatitis. Cochrane Database of Systematic Reviews. 2007;CD005165.
Metadata
Title
Fighting Fire with Fire: Is it Time to Use Probiotics to Manage Pathogenic Bacterial Diseases?
Authors
John Heineman
Sara Bubenik
Stephen McClave
Robert Martindale
Publication date
01-08-2012
Publisher
Current Science Inc.
Published in
Current Gastroenterology Reports / Issue 4/2012
Print ISSN: 1522-8037
Electronic ISSN: 1534-312X
DOI
https://doi.org/10.1007/s11894-012-0274-4

Other articles of this Issue 4/2012

Current Gastroenterology Reports 4/2012 Go to the issue

Gastrointestinal Infections (W Coyle, Section Editor)

Cytomegalovirus Infection and the Gastrointestinal Tract

Neuromuscular Disorders of the Gastrointestinal Tract (A Foxx-Orenstein, Section Editor)

Meditation over Medication for Irritable Bowel Syndrome? On Exercise and Alternative Treatments for Irritable Bowel Syndrome

Neuromuscular Disorders of the Gastrointestinal Tract (A Foxx-Orenstein, Section Editor)

When is Irritable Bowel Syndrome Not Irritable Bowel Syndrome? Diagnosis and Treatment of Chronic Functional Abdominal Pain

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine